US Cost Effectiveness of Darunavir/ Ritonavir 600/100mg bid in Treatment- Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial.

MLA

Brogan, Anita, et al. “US Cost Effectiveness of Darunavir/ Ritonavir 600/100mg Bid in Treatment- Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial.” PharmacoEconomics, vol. 28, Jan. 2010, pp. 129–46. EBSCOhost, https://doi.org/10.2165/11587490-000000000-00000.

APA

Brogan, A., Mauskopf, J., Talbird, S. E., & Smets, E. (2010). US Cost Effectiveness of Darunavir/ Ritonavir 600/100mg bid in Treatment- Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial. PharmacoEconomics, 28, 129–146. https://doi.org/10.2165/11587490-000000000-00000

Chicago

Brogan, Anita, Josephine Mauskopf, Sandra E. Talbird, and Erik Smets. 2010. “US Cost Effectiveness of Darunavir/ Ritonavir 600/100mg Bid in Treatment- Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial.” PharmacoEconomics 28 (January): 129–46. doi:10.2165/11587490-000000000-00000.